Shift Bioscience is a technology company.
Shift Bioscience has raised $16.0M across 1 funding round.
Shift Bioscience has raised $16.0M in total across 1 funding round.
Shift Bioscience has raised $16.0M in total across 1 funding round.
Shift Bioscience's investors include Amadeus Capital Partners, Business Growth Fund, Downing Ventures, Parkwalk Advisors.
Shift Bioscience is a biotechnology company developing AI-powered cell simulation platforms to achieve safe cellular rejuvenation, aiming to reverse aging and treat age-related diseases without altering cell identity.[1][2][3] It builds virtual cell technology that integrates machine learning with multiomic datasets to identify rejuvenation targets, such as novel genes like SB000, targeting conditions including age-driven hearing loss, MASH (metabolic dysfunction-associated steatohepatitis), and systemic sclerosis.[1][4][6] The company serves the healthcare and biotech research sectors by providing aging biomarker development and gene-based interventions, with a pipeline progressing toward human-validated cellular age reversal.[1][2] Founded in 2017 and based in Cambridge, UK, Shift has raised $18M in funding, demonstrating growth through seed investments and facility expansions.[3][4]
Shift Bioscience was founded in 2017 by Dr. Daniel Ives (CEO) and Dr. Brendan Swain (CSO), leveraging facilities at the University of Cambridge's Gurdon Institute, a computational team in Toronto, Canada, and drug development expertise from alumni of Alnylam, Moderna, and GSK.[1] The idea emerged from advances in epigenetic research and machine learning, focusing on safer cellular reprogramming to avoid pluripotency-inducing genes that risk cancer.[3] Early traction included proprietary multiomic datasets and virtual cell models, culminating in a $16M seed round in 2024 led by BGF, with participation from F-Prime Capital, Kindred Capital, and Jonathan Milner, bringing total funding to $18M.[4] Pivotal moments feature presentations at the 2024 Gordon Research Conference on Systems Aging and the discovery of SB000, a single-gene target for rejuvenation.[4][6]
Shift Bioscience stands out in biotech through its integration of AI and cell biology for accelerated target discovery:
Shift Bioscience rides the convergence of AI and longevity biotech, capitalizing on trends in cellular reprogramming pioneered by figures like David Sinclair and Yamanaka, but with a safer, simulation-guided twist.[3] Timing aligns with surging investor interest in age-reversal tech—evidenced by its early funding as one of the first cell simulation biotechs—and regulatory shifts toward preventive healthcare over reactive sick-care.[2][4] Market forces like aging populations, AI advancements in drug discovery (e.g., AlphaFold's impact), and multiomic data explosion favor Shift, enabling faster pipelines for diseases like hearing loss and MASH.[1][4] It influences the ecosystem by open-sourcing metric frameworks, attracting top talent, and partnering with VCs like F-Prime, potentially shifting biotech from trial-and-error to predictive modeling.[1][8]
Shift Bioscience is poised to advance its pipeline into clinical trials, prioritizing SB000 and expanding IP around AI-discovered rejuvenation genes, fueled by North American expansion and further platform refinements.[6][7] Trends like multimodal AI integration and epigenetic therapeutics will shape its path, amplifying impact amid a $100B+ longevity market. Its influence may evolve from target discovery to leading preventative medicine, validating cellular age reversal in humans and inspiring AI-biotech hybrids—positioning it as a frontrunner in ending aging's morbidity.[1][4]
Shift Bioscience has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $16.0M Seed | Amadeus Capital Partners, Business Growth Fund, Downing Ventures, Parkwalk Advisors |